A Within-Subject Single Dose Trial on the Effects of Bremelanotide on Social Cognition and Behaviour

Phase 2

Recruiting

• Conditions: Autism Spectrum Disorder; Mental Health - Autistic spectrum disorders

• Registration Number: ACTRN12615001059550
• Lead Sponsor: niversity of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-10-12
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 60

Inclusion Criteria

Participants must meet DSM-IV-TR criteria for Autistic Disorder, Pervasive Developmental Disorder-Not Otherwise Specified or Asperger’s Disorder.

Exclusion Criteria

Clinical participants will be excluded if they meet the following exclusion criteria:

Severe depression with suicidal thought/and or actions, High blood pressure, Severe cardiovascular problems, Kidney disease, Psychosis, Addiction to nicotine and/or illicit substances.

Concomitant medications that exclude participants: use of
phosphodiesterase type 5 inhibitor (e.g., erectile dysfunction) medications.

Study & Design

• Study Type: Interventional
• Study Design: Not specified